

tion could occur because of the long-term use of anticoagulant therapy. Hence, in our patient, warfarin was responsible for the recanalization of the side branch. There is no case of recanalization of the unligated side branch of the LIMA after successful coil occlusion in patients who consumed warfarin owing to valve replacement.

The data is scarce regarding the treatment of recanalization of the side branch of LIMA in patients who consume warfarin. If the recanalization of the side branch was detected in these patients, different options may be considered such as vascular plugs, graft stents, gelatin sponge particles, combined drug-eluting and covered stents. As our patient's LIMA diameter was relatively small for placing the vascular plug and graft stent, a coil reocclusion procedure was preferred. We used numerous large-sized coils to complete the occlusion of the vessel. The final angiographic view was satisfying with respect to total vessel occlusion.

## Conclusion

Eventually after coil occlusion procedure, patients with admitted angina consuming warfarin should be considered in terms of recanalization. In cases when a coil occlusion procedure is preferred, the final result of procedure should be satisfactory in terms of total mechanical occlusion of the vessel using a coil rather than only stopping the flow.

## References

1. Barber HB, Standeven JW, Reese J. Twelve-year experience with internal mammary artery for coronary artery bypass. *Thorac Cardiovasc Surg* 1985; 90: 668-75.
2. Valensi P, Huard JP, Giroux C, Attali JR. Factors involved in cardiac autonomic neuropathy in diabetic patients. *J Diabetes Complications* 1997; 11: 180-7. [\[CrossRef\]](#)
3. Ayres RW, Chien-Tai L, Benzuly KH, Hill GA, Rossen JD. Transcatheter of an internal mammary artery bypass graft side branch causing coronary steal syndrome. *Cathet Cardiovasc Diagn* 1994; 31: 301-13. [\[CrossRef\]](#)
4. Akilli A, Duygu H, Ertürk U, Yıldız A, Zoghi M, Özerkan F. Transbrachial coil occlusion of unligated thoracic side branch of arterial graft of internal mammary artery leading to silent ischemia in a diabetic patient. *Int J Cardiol* 2006; 113: 16-8. [\[CrossRef\]](#)
5. Moreno N, da Silva Castro A, Pereira A, Silva JC, Almeida PB, Andrade A, et al. Ischemia induced by coronary steal through a patent mammary artery side branch: a role for embolization. *Rev Port Cardiol* 2013; 32: 531-4. [\[CrossRef\]](#)
6. Sanghvi AB, Diaz Fernandez JF, Gomez Menchero AE. Transradial occlusion of a large intercostal branch of a left internal mammary artery graft with the novel amplatzer vascular plug 4 using a 4 French diagnostic catheter: treatment of coronary steal phenomenon. *J Invasive Cardiol* 2011; 23: 113-6.
7. Enriquez J, Javadi S, Murthy R, Ensor J Jr, Mahvash A, Abdelselam ME, et al. Gastroduodenal artery recanalization after transcatheter fiberoil embolization for prevention of hepaticocenteric flow: incidence and predisposing technical factors in 142 patients. *Acta Radiol* 2013; 54: 790-4. [\[CrossRef\]](#)

**Video 1.** A large side branch originating from the left internal mammary artery and cessation of the side branch of left internal mammary artery flow with coil occlusion.

**Video 2.** Recanalization of the side branch of the left internal mammary artery, detachment of the proximal part of the coil attachment apparatus, implantation of the drug-eluting stent, and cessation of the side branch of left internal mammary artery flow with coil reocclusion.

**Address for Correspondence:** Levent Cerit, Near East University Hospital, Nicosia-Turkish Republic of Northern Cyprus  
Phone: +90 392 675 10 00 E-mail: drcerit@hotmail.com

©Copyright 2015 by Turkish Society of Cardiology - Available online at [www.anatoljcardiol.com](http://www.anatoljcardiol.com)



DOI: 10.5152/AnatolJCardiol.2015.6449

# Transcatheter ventricular septal defect closure: Should we feel comfortable after many years?

Ercan Tutar, Mehmet Ramoğlu, Ömer Çiftçi, Tayfun Uçar, Timuçin Altın\*  
Departments of Pediatric Cardiology and \*Cardiology, Faculty of Medicine, Ankara University; Ankara-Turkey

## Introduction


Ventricular septal defect (VSD) is the most common congenital heart defect. Indicated closure is performed either by surgery or by using a transcatheter route in eligible patients (1). Although closure rates are similar in the transcatheter and surgical VSD closure, both the transcatheter closure of a VSD and surgery are not a complication-free procedure (2, 3). The occurrence of a complete atrioventricular block (CAVB) is one of the major complications of transcatheter closure, particularly in perimembranous-type VSDs. CAVB may occur acutely during the procedure or after a few days or months of the transcatheter closure (3-8). Late development of CAVB is an alarming complication because of the risk of sudden death. According to our knowledge, the longest interval between the procedure and the occurrence of CAVB in the literature is 20 months (5). Herein, we report the case of an 8-year-old girl who developed CAVB at 51 months after an uneventful closure of muscular VSD located just below the membranous septum (known as high-muscular VSD).

## Case Report

Transcatheter VSD closure was performed in the patient at the age of 3.5 years and weighed 15 kg. She had no significant medical problem other than VSD. Her ECG did not show any conduction abnormality. The size of the defect was measured to be 5.5 mm via transesophageal echocardiography (TEE). VSD was closed in a standard manner under the guidance of TEE and fluoroscopy. A 6-mm membranous VSD occluder (Amplatzer) was used. Hemodynamic measurements showed that the Qp/Qs ratio was 3 and the mean pulmonary artery pressure was 28 mm Hg. The intervention was uneventful, and there was only right bundle branch block (RBBB) without any atrioventricular conduction abnormality after the procedure. Transthoracic echocardiography (TTE) performed on the following day showed a complete closure of the defect with good device position (Fig. 1). Routine follow-ups were performed with ECG, TTE, and Holter monitoring at 1, 3, and 6 months as well as every 6 months after the procedure, thereafter. At her last follow-up visit, she was aged 7.5 years. Her ECG, TTE, and Holter monitoring did not show any abnormalities, except RBBB. She experienced a brief syncopal episode at 51 months after the transcatheter VSD closure. She was urgently referred to our clinic because of significant bradycardia. Upon arrival, her ECG showed CAVB with a ventricular rate of 35/min (Fig. 2). Clinical studies showed no obvious reason for CAVB. Transvenous transient endocardial pacemaker was urgently placed and permanent endocardial pacemaker was implanted without any complication.


## Discussion

A major concern for percutaneous perimembranous VSD closure is the risk of CAVB. The frequency of this alarming complication in



**Figure 1. Transthoracic 2-dimensional echocardiography in 4-chamber view shows a good position of the membranous ventricular septal defect occluder after implantation.**

LA - left atrium; LV - left ventricle; RA - right atrium; RV - right ventricle



**Figure 2. A 12-lead standard surface ECG shows complete atrioventricular block**

patients was reported to be 1%–5% (3-8). There may be an early occurrence of CAVB during the procedure. However, in most patients, CAVB develops days or even months after the intervention. The latest occurrence of CAVB in the published literature was 20 months after the procedure (5, 8). The development of CAVB is mainly related to the adjacency of the conduction system to the borders of the perimembranous VSD. Direct compression of the conduction system in early CAVB and fibrosis secondary to the inflammation provoked by the device in late CAVB has been suggested as possible mechanisms (5, 8). Although the VSD of the presented case was not perimembranous, it only had a muscular rim with a size of 2 mm separating it from the membranous septum. Therefore, the same mechanisms responsible for CAVB development may be accountable for CAVB development in this patient as well.

CAVB can also occur after surgical perimembranous VSD closure; however, its incidence in recent series is less than 1% in most centers (1, 9, 10). A recent multicenter study that involved the surgical perimembranous VSD closure of 4432 patients reported an incidence rate of 1.1% of CAVB requiring permanent pacemaker placement (9). Thus, the risk of

surgical atrioventricular block is equal to or lower than the risk of transcatheter closure. Another important point that should be considered is that CAVB generally occurs early after operation in surgical patients; however, in percutaneously treated patients, the timing of CAVB development is completely unpredictable, and it is usually a late event (5, 8, 9).

## Conclusion

The occurrence of CAVB after more than 4 years of intervention in our patient suggests that clinicians should be aware of the lifelong risk of CAVB development in patients undergoing percutaneous VSD closure, particularly those who had VSDs located near the membranous septum. The decision makers should think twice before percutaneous VSD closure, and the potential lifelong risk of CAVB should be considered when counseling families regarding options for VSD closure.

## References

- Bonello B, Foilloux V, Le Bel S, Fraisse A, Kreitmann B, Metras D. Ventricular septal defects. In: Da Cruz EM, Ivy D, Jagers J, editors. Pediatric and congenital cardiology, cardiac surgery and intensive care. London: Springer-Verlag; 2014. p. 1455-78. [\[CrossRef\]](#)
- Xunmin C, Shisen J, Jianbin G, Haidong W, Lijun W. Comparison of results of surgical and Amplatzer device closure of perimembranous ventricular septal defects. *Int J Cardiol* 2007; 120: 28-31. [\[CrossRef\]](#)
- Thanopoulos BD, Rigby ML, Karanasios E, Stefanadis C, Blom N, Ottenkamp J, et al. Transcatheter closure of perimembranous ventricular septal defects in infants and children using the Amplatzer perimembranous septal defect occluder. *Am J Cardiol* 2007; 99: 984-9. [\[CrossRef\]](#)
- Zuo J, Xie J, Yi W, Yang J, Zhang J, Li J, et al. Results of transcatheter closure of perimembranous ventricular septal defect. *Am J Cardiol* 2010; 106: 1034-7. [\[CrossRef\]](#)
- Butera G, Carminati M, Chessa M, Piazza L, Micheletti A, Negura DG, et al. Transcatheter closure of perimembranous ventricular septal defects. Early and long-term results. *J Am Coll Cardiol* 2007; 50: 1189-95. [\[CrossRef\]](#)
- Wei Y, Wang X, Zhang S, Hou L, Wang Y, Xu Y, et al. Transcatheter closure of perimembranous ventricular septal defects (ventricular septal defect) with ventricular septal defect occlude: early and mid-term results. *Heart Vessels* 2012; 27: 398-404. [\[CrossRef\]](#)
- Holzer R, de Giovanni J, Walsh KP, Tometzki A, Goh T, Hakim F, et al. Transcatheter closure of perimembranous ventricular septal defects using the Amplatzer membranous ventricular septal defect occluder: Immediate and midterm results of an international registry. *Catheter Cardiovasc Interv* 2006; 68: 620-8. [\[CrossRef\]](#)
- Carminati M, Butera G, Chessa M, De Giovanni J, Fisher G, Gewillig M, et al. Transcatheter closure of perimembranous ventricular septal defects: results of the European Registry. *Eur Heart J* 2007; 28: 2361-8. [\[CrossRef\]](#)
- Tucker EM, Pyles LA, Bass JL, Moller JH. Permanent pacemaker for atrioventricular conduction block after operative repair of perimembranous ventricular septal defect. *J Am Coll Cardiol* 2007; 50: 1196-200. [\[CrossRef\]](#)
- Van Doorn C, de Leval MR. Ventricular septal defects. In: Stark J, de Leval M, Tsang VT editors. *Surgery for Congenital Heart Defects*. West Sussex: John Wiley&Sons, Ltd; 2006. p. 355-71. [\[CrossRef\]](#)

**Address for Correspondence:** Dr. Erçan Tutar  
Defne Sitesi, 8. Blok, No: 37, 06800 Ümitköy, Ankara-Türkiye  
Phone: +90 532 345 12 01  
Fax: +90 312 428 23 00  
E-mail: ercantutar@gmail.com

©Copyright 2015 by Turkish Society of Cardiology - Available online at [www.anatoljcardiol.com](http://www.anatoljcardiol.com)

DOI:10.5152/AnatolJCardiol.2015.6410

